Aurora Cannabis vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Aurora Cannabis Inc (ACB)

Q3 20268 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

September 20268 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

Latest8 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.